Boosted production of antibodies which neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following mRNA vaccination - a case study.
JSON
Ravlo E, Ianevski A, Starheim E, Wang W, Ji P, Lysvand H, Smura T, Kivi G, Voolaid M, Plaan K, Ustav M, Zusinaite E, Tenson T, Kurg R, Oksenych V, Walstad K, Nordbø SA, Kaarbø M, Ernits K, Bjørås M, Kainov DE, Høysæter Fenstad M
Int J Infect Dis - (-) - [2023-10-16; online 2023-10-16]
Vaccinated convalescents do not develop severe COVID-19 after infection with new SARS-CoV-2 variants. We questioned how mRNA vaccination of convalescents provides protection from emerging virus variant. From the cohort of 71 convalescent plasma donors, we identified a patient who developed immune response to infection with SARS-CoV-2 variant of 20A clade and who subsequently received mRNA vaccine encoding S protein of strain of 19A clade. We showed that vaccination increased the production of immune cells and anti-S antibodies in the serum. Serum antibodies neutralized not only 19A and 20A, but also 20B, 20H, 21J and 21K virus variants. One of the serum antibodies (100F8) completely neutralized 20A, 21J and partially 21K strains. 100F8 was structurally similarly to published Ab188 antibody, which recognized non-conserved epitope on the S protein. We proposed that 100F8 and other serum antibodies of the patient which recognized non- and conserved epitopes of the S protein, could have additive or synergistic effect to neutralize various virus variants. Thus, mRNA vaccination could be beneficial for convalescents because it boosts production of neutralizing antibodies with broad-spectrum activity. -.
PubMed 37852599
DOI 10.1016/j.ijid.2023.10.011
Crossref 10.1016/j.ijid.2023.10.011
pii: S1201-9712(23)00748-8